Evaluates survival benefit of bevacizumab added to chemotherapy in lung cancer, suggesting effective treatment strategy.
The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)
No takes yet. Share an insight, caveat, or question.
Sandler et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: